𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Tumor necrosis factor-α antagonists and neuropathy

✍ Scribed by Joerg-Patrick Stübgen

Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
586 KB
Volume
37
Category
Article
ISSN
0148-639X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Life-threatening histoplasmosis complica
Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor α antagonists infliximab and etanercept
✍ Jong-Hoon Lee; Nancy R. Slifman; Sharon K. Gershon; Evelyne T. Edwards; William 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 85 KB

## Abstract ## Objective Two tumor necrosis factor α (TNFα) antagonists were recently licensed in the US. Infliximab was licensed in 1998 for the treatment of Crohn's disease (CD), and since 1999, it has been licensed in combination with methotrexate for treatment of rheumatoid arthritis (RA). Eta

Increased risk of coccidioidomycosis in
Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor α antagonists
✍ Laurie Bergstrom; David E. Yocum; Neil M. Ampel; Isidro Villanueva; Jeffrey Liss 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 91 KB 👁 2 views

## Abstract ## Objective To describe a group of patients who were treated with tumor necrosis factor α (TNFα) antagonists and who developed coccidioidomycosis, and to test the hypothesis that patients with inflammatory arthritis receiving TNFα antagonist therapy are at higher risk for developing s